Valuation: Jade Biosciences, Inc.

Market Cap 1.3B 1.13B 1.05B 966M 1.82B 124B 1.85B 12.35B 4.85B 62.18B 4.9B 4.79B 206B P/E 2026 *
-8.44x
P/E 2027 * -8.52x
Enterprise Value 1.05B 908M 848M 778M 1.46B 99.93B 1.49B 9.95B 3.91B 50.09B 3.94B 3.86B 166B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.34%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day-1.26%
1 week+11.19%
Current month+11.19%
1 month-2.53%
3 months-14.92%
6 months+43.34%
Current year+42.32%
1 week 18.55
Extreme 18.55
23
1 month 18.54
Extreme 18.54
23.33
Current year 12.45
Extreme 12.45
28
1 year 6.67
Extreme 6.67
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 28/04/2025
Director of Finance/CFO 38 14/07/2025
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 50 28/04/2025
Director/Board Member 42 28/04/2025
Chairman 57 28/04/2025
Date Insider Type Main position Quantity % Market Cap.
25/6/26 Free

Director

47,675 0.0966%
12/2/26 Free

General Counsel

196,875 0.4280%
12/2/26 Free

Chief Technology Officer

288,750 0.6277%
Change 5-day change 1-year change 3-year change Capi.($)
-1.26%+11.19%+193.19% - 1.3B
+0.99%+1.78%+5.07%+16.49% 49.47B
+3.71%+9.40%+486.14%+579.98% 43.97B
+5.60%+10.21%+20.85%+81.78% 39.6B
+2.70%+1.57%+32.71%+9.07% 39.29B
+2.21%+6.75%+20.20%+54.40% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+35.99%+124.45% 16.49B
-0.11%+2.41%+5.03%+20.47% 14.01B
+0.75%+15.04%+79.84%+29.70% 12.77B
Average +1.78%+6.81%+97.67%+114.54% 26.62B
Weighted average by Cap. +2.52%+6.13%+105.60%+138.67%

Financials

2026 *2027 *
Net sales - -
Net income -173M -150M -140M -128M -241M -16.48B -245M -1.64B -644M -8.26B -650M -636M -27.31B -191M -165M -154M -142M -266M -18.19B -271M -1.81B -711M -9.12B -718M -702M -30.15B
Net Debt -254M -219M -205M -188M -353M -24.13B -359M -2.4B -943M -12.09B -952M -931M -39.98B -300M -260M -243M -223M -419M -28.58B -425M -2.85B -1.12B -14.32B -1.13B -1.1B -47.35B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
07/08/26 US$21.96 -1.26% 481,234
06/08/26 US$22.24 +2.49% 1,112,753
05/08/26 US$21.70 +1.64% 1,265,240
04/08/26 US$21.35 +11.49% 1,687,405
03/08/26 US$19.15 -3.04% 651,162
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.96USD
Average target price
48.50USD
Spread / Average Target
+120.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock